Effect of LIXIsenatide on the Renal System

Phase 4

Completed

• Conditions: Diabetic Nephropathy; Diabetic Kidney Disease; Diabetes Mellitus; Glucagon-Like Peptide 1
• Interventions: Drug: Insulin glulisine; Drug: Lixisenatide

• Registration Number: NCT02276196
• Lead Sponsor: Amsterdam UMC, location VUmc

Brief Summary

Based on preclinical and small-sized studies in non-diabetic individuals, incretin-based therapies, i.e. glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, may hold promise in preventing the onset and progression of diabetic kidney disease. However, the potential renoprotective effects of these agents, that are believed to be effectuated "beyond glucose control", have not been sufficiently detailed in human diabetes.

Therefore, the present study aims to explore the mechanistic and clinical effects of GLP-1 receptor agonists on renal physiology and biomarkers in patients with type 2 diabetes.

Forty patients with insulin-treated type 2 diabetes will undergo an eight week intervention with lixisenatide or insulin glulisine in order to assess changes in the outcome parameters.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-09
• Study First Submitted: 2014-10-16
• Study First Submitted QC: 2014-10-27
• Study First Posted: 2014-10-28
• Status Verified: 2016-02
• Primary Completion: 2016-04
• Study Completion: 2016-04
• Last Update Submitted: 2016-04-28
• Last Update Posted: 2016-04-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Patients with type 2 diabetes (HbA1c: 6.5-10.0% or 48-86 mmol/mol)
• Stable treatment with basal insulin glargine (dose ±20%) and metformin or basal insulin glargine (dose ±20%) alone for at least 3 months
• Fasting plasma glucose <10 mmol/L or the use of >50 units of basal insulin glargine
• Females must be post-menopausal
• Caucasian
• Age: 35 - 75 years
• Body Mass Index: >25 kg/m2
• Hypertension should be under control, i.e. <140/90 mmHg, and treated with an angiotensin-converting enzyme inhibitor or angiotensin-II-receptor blocker for at least 3 months.
• Albuminuria should be treated with an angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin-II-receptor blocker (ARB) for at least 3 months.

Exclusion Criteria

• Current/chronic use of the following medication: thiazolidinediones, sulfonylurea derivatives, GLP-1 receptor agonists, dipeptidyl peptidase (DPP)-4 inhibitors, glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics, antipsychotics, tricyclic antidepressants and monoamine oxidase inhibitors. Subjects on diuretics, will only be excluded when these drugs cannot be stopped for the duration of the study.
• Chronic use of non-steroidal anti-inflammatory drugs will not be allowed, unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e. sports injury, head-ache or back ache). However, no such drugs can be taken within a time-frame of 2 weeks prior to renal-testing
• Hypoglycemia unawareness based on investigator judgment
• History of severe hypoglycemia that required emergency hospital treatment within 3 months prior to screening
• Estimated GFR <60 mL/min/1.73m2 (determined by the Modification of Diet in Renal Disease (MDRD) study equation)
• Pregnancy
• Current urinary tract infection and active nephritis
• Recent (<6 months) history of cardiovascular disease, including: acute coronary syndrome, chronic heart failure (New York Heart Association grade II-IV), stroke or transient ischemic neurologic disorder
• Complaints compatible with or established gastroparesis, neurogenic bladder and/or incomplete bladder emptying (as determined by ultrasonic bladder scan)
• Active liver disease or a 3-fold elevation of liver enzymes (aspartate aminotransferase/alanine aminotransferase) at screening
• History of or actual pancreatic disease
• History of or actual malignancy (except basal cell carcinoma)
• History of or actual severe mental disease
• Substance abuse (alcohol: defined as >4 units/day)
• Allergy to any of the agents used in the study
• Individuals who are investigator site personnel, directly affiliated with the study, or are immediate (spouse, parent, child, or sibling, whether biological or legally adopted) family of investigator site personnel directly affiliated with the study
• Inability to understand the study protocol or give informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Insulin glulisine	Insulin glulisine	Insulin glulisine will be administered subcutaneously, once daily for 8 weeks
Lixisenatide	Lixisenatide	Lixisenatide will be administered subcutaneously, once daily for 8 weeks

Primary Outcome Measures

Name	Time	Method
Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF)	8 weeks	ml/min

Secondary Outcome Measures

Name	Time	Method
Renal damage, measured by urine biomarkers	8 weeks	enzyme immuno assay
Renal tubular function	8 weeks	e.g. percentage (%)
Blood Pressure	8 weeks	mmHg

Trial Locations

Locations (1)

VU Universtiy Medical Center; 🇳🇱 Amsterdam, Netherlands